USPSTF Recommends Screening for Latent TB Infection
Task force recommends screening asymptomatic adults at increased risk for latent TB infection
Tuberculosis
Bedaquiline-Pretomanid-Linezolid Regimens Compared for XDR TB
Overall risk-benefit ratio seems to favor patients receiving linezolid at dose of 600 mg for 26 weeks
Among Persons With HIV, More Finish Short-Course TB Prophylaxis
Treatment completion 90.4 percent for three months of rifapentine-isoniazid versus 50.5 percent for six months of isoniazid
Four-Month Rifapentine Regimen With Moxifloxacin Noninferior for TB
Rifapentine-based regimen with moxifloxacin noninferior to six-month control regimen of rifampin, isoniazid, pyrazinamide, ethambutol
MPR Weekly Dose Podcast Episode 55
Results from the survey assessing willingness to receive a COVID vaccine; Dr. Fauci shares that he is ‘cautiously optimistic’ a vaccine could arrive before year’s end; And the breaking news that remdesivir (Veklury) has gained FDA approval.
Shorter-Course Regimen Safe, Effective for TB Treatment
The randomized, open-label, controlled trial (Study 31/A5349) had more than 2500 participants ages 12 years and older and included 214 people with HIV.
FDA: Tuberculosis Drugs May Contain Nitrosamine Impurities
Currently, there is no available evidence to assess the carcinogenic potential of MNP and CPNP.
Short-Course Rifamycin-Based Regimens Preferred for Latent TB
Shorter regimens favored over longer course of isoniazid monotherapy for latent TB infection.
Review: Areas of Pediatric Medical Overuse Identified
A recent systematic review identified several established as well as emerging practices utilized in the pediatric setting that were associated with overuse of medical care.
Pretomanid Approved as Part of a New Regimen for Highly Drug-Resistant Tuberculosis
The FDA has approved pretomanid tablets (TB Alliance) in combination with bedaquiline and linezolid for the treatment of adults with pulmonary extensively drug resistant (XDR), treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB).
